Night Building Banner

Our Cyclotron

TMIC operates a Siemens Eclipse HP Cyclotron, complemented by advanced radiopharmaceutical synthesis equipment, including six shielded hot cells and a fully equipped quality control laboratory. 

Siemens Eclipse HP Cyclotron 

TMIC operates a Siemens Eclipse HP cyclotron as part of its on-site radiopharmacy facility. The cyclotron supports the production of radionuclides used in the preparation of PET radiopharmaceuticals for clinical imaging. The facility includes two beam lines and dedicated target systems for radionuclide production. 

Cyclotron Details 

  • Siemens Eclipse HP cyclotron  
  • Energy: 11 MeV 
  • Target Current: 60 microamperes per beam line, 130 microamperes.  
  • Beam lines: 2 each with 3.7Ci per run on each target. 
  • Targets: 2 each F-18, 1 each N-13  
  • Chemistry Modules: 2 each Siemens ExploraFDG4 and 1 Ge tracer lab MX. 

The cyclotron and associated production systems are operated and maintained according to applicable operational, quality, and regulatory requirements. 

Advanced Molecular Banner

Specialist Cyclotron Management

TMIC’s cyclotron operations are managed by Cyclomedical, a specialist cyclotron operator with expertise in cyclotron operations and radiopharmaceutical production. The cyclotron management service supports the operation of the facility and the production and quality-control processes associated with PET radiopharmaceuticals. 

Radiopharmaceutical production is performed according to established procedures and applicable regulatory and quality requirements. The production process incorporates controlled systems covering areas such as facilities and equipment, materials, production, quality systems, packaging and labelling, and laboratory controls. 

Radiopharmaceutical Production 

Specialized Radiopharmaceuticals for Molecular Imaging 

Radiopharmaceuticals are an essential part of PET imaging. Different radiopharmaceuticals interact with specific biological processes or molecular targets, allowing PET to provide information relevant to different clinical questions. TMIC’s integrated radiopharmacy supports the preparation of radiopharmaceuticals for applications across oncology, cardiology, and neurology. 

Oncology 

Radiopharmaceuticals used in oncology can provide information about different biological characteristics of tumours and may support the evaluation of disease, staging, treatment response, or specific tumour types. 

  • 18F-FDG - used across a range of oncology applications to assess abnormal glucose metabolism. 
  • 18F-NaF - used to evaluate bone-forming activity and suspected bone involvement in selected clinical situations. 
  • 18F-PSMA and 68Ga-PSMA - used for molecular imaging applications involving prostate cancer. 
  • 68Ga-DOTATATE - targets somatostatin receptors and is used for imaging selected neuroendocrine tumours. 
  • 18F-Choline - used in selected oncology applications, including prostate cancer. 
  • 18F-FES - used for selected imaging applications involving oestrogen receptor-positive breast cancer. 
  • 18F-FET - used in selected applications involving primary and recurrent brain tumours. 
  • 18F-FDOPA - used in selected oncology and neurological applications. 
  • 18F-MISO - used in selected clinical settings to evaluate tumour hypoxia. 

Cardiology 

13N-ammonia (13N-NH3) is produced for cardiac PET imaging and can be used to assess myocardial perfusion at rest and during pharmacological stress in patients with suspected or established coronary artery disease. 

Neurology 

Radiopharmaceuticals such as 18F-FDG, 18F-FDOPA, and 18F-FET may be used for selected neurological imaging applications. Depending on the radiopharmaceutical and clinical indication, PET can provide information about brain metabolism or specific molecular processes. 

The choice of radiopharmaceutical depends on the patient’s clinical indication and the information required by the referring physician. 

Radiopharmaceuticals Available at TMIC.

Radiopharmaceutical Production Method  Clinical Applications 
18F-FDG  Cyclotron + synthesizer  Oncology, neurology, cardiology 
18F-DOPA  Cyclotron + synthesizer  Oncology
18F-FET  Cyclotron + synthesizer  Oncology, neurology 
18F-MISO  Cyclotron + synthesizer  Oncology
18F-PSMA  Cyclotron + synthesizer  Oncology
18F-FES  Cyclotron + synthesizer  Oncology
18F-Choline  Cyclotron + synthesizer  Oncology
68Ga-PSMA  Generator + synthesis system  Oncology
68Ga-DOTATATE  Generator + synthesis system  Oncology
13N-NH3  Cyclotron  Cardiology
18F-NaF  Cyclotron + synthesizer  Oncology
In-the-pipeline 
18F-Fluorothymidine  Cyclotron + synthesizer  Oncology
18F-Flurpiridaz  Cyclotron + synthesizer  Cardiology

Radiopharmaceutical Synthesis 

Precision in Every Preparation 

Radiopharmaceutical synthesis is the controlled process of incorporating a radioactive isotope into a chemical or biological compound designed for a specific imaging application. Following radionuclide production, the radioactive material is incorporated into the radiopharmaceutical using specialized synthesis systems. TMIC’s radiopharmacy includes automated synthesis equipment that supports controlled and reproducible radiopharmaceutical preparation. 

The facility includes: 

  • Two Siemens ExploraFDG4 synthesis modules 
  • One GE TRACERlab MX system 

A GE FASTlab 2 synthesis system is planned for addition to the radiopharmacy, further expanding TMIC’s radiopharmaceutical production capabilities. 

Automated synthesis systems support standardized and reproducible preparation while helping reduce the need for direct handling of radioactive materials. 

Request a Call

We look forward to welcoming you and helping you take the next step in your health journey with confidence.

Request a Callback Call: 80077 Email: info@tmic.ae